Brodalumab: all 43 studies that test it

Page 1 of 1. Open to participants first (1), then studies with results posted, then the rest; newest registration first within each.

• Brodalumab in the Treatment of Immune-Related Adverse EventsRecruitingNCT06673329Phase 1
• Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to UstekinumabTerminatedNCT04533737Phase 4Results posted
• Efficacy and Safety of Brodalumab in Adolescents From 12 to 17 Years of Age With Moderate-to-severe Plaque PsoriasisTerminatedNCT04305327Phase 3Results posted
• Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed IL-17A TherapiesCompletedNCT03403036Phase 4Results posted
• A Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque PsoriasisCompletedNCT03331835Phase 4Results posted
• A Bioequivalence Study Comparing a Single 1.5mL Dose of Brodalumab vs. Two Doses (1.0mL + 0.5mL) of BrodalumabCompletedNCT02173392Phase 1Results posted
• Study of Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic ArthritisTerminatedNCT02029495Phase 3Results posted
• Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic ArthritisCompletedNCT02024646Phase 3Results posted
• Brodalumab Drug-Drug Interaction (DDI) and Intensive Pharmacodynamic (PK) Study in Psoriasis SubjectsCompletedNCT01937260Phase 1Results posted
• Study of Efficacy and Safety of Brodalumab Compared With Placebo in Adults With Inadequately Controlled Asthma With High Bronchodilator ReversibilityTerminatedNCT01902290Phase 2Results posted
• Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis SubjectsTerminatedNCT01708629Phase 3Results posted
• P3 Study Brodalumab in Treatment of Moderate to Severe Plaque PsoriasisTerminatedNCT01708603Phase 3Results posted
• Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab in Moderate to Severe Plaque Psoriasis SubjectsTerminatedNCT01708590Phase 3Results posted
• AMG 827 in Subjects With Psoriatic ArthritisTerminatedNCT01516957Phase 2Results posted
• Long-term Safety Study of Brodalumab in Adults With Crohn's DiseaseTerminatedNCT01199302Phase 2Results posted
• A Study to Evaluate the Dosing of AMG 827 for Subjects With Inadequately Controlled AsthmaCompletedNCT01199289Phase 2Results posted
• Brodalumab (AMG 827) in Adults With Moderate to Severe Crohn's DiseaseTerminatedNCT01150890Phase 2Results posted
• Study to Assess the Long-term Safety, Tolerability, and Efficacy of AMG 827 in Subjects With PsoriasisTerminatedNCT01101100Phase 2Results posted
• Safety and Efficacy of AMG 827 in Subjects With RATerminatedNCT01059448Phase 2Results posted
• Brodalumab (AMG 827) in Rheumatoid Arthritis (RA) Participants With Inadequate Response to MethotrexateCompletedNCT00950989Phase 2Results posted
• Study to Evaluate the Safety, PK, PD and Efficacy of AMG 827 in Adults With Rheumatoid ArthritisCompletedNCT00771030Phase 1/2Results posted
• Molecular Characteristics of Brodalumab in Hidradenitis SuppurativaCompletedNCT04979520Early Phase 1
• Brodalumab in Palmoplantar PsoriasisStatus unknownNCT04622033Phase 4
• A Phase 4 Study of Brodalumab (KHK4827) in Subjects With Moderate to Severe Plaque PsoriasisWithdrawnNCT04614298Phase 4
• A Study of KHK4827 in Patients With Systemic SclerosisCompletedNCT04368403Phase 1
• Dose Reduction of IL17 and IL23 Inhibitors in PsoriasisCompletedNCT04340076Phase 4
• Adjusted Brodalumab Dose Compared With Standard Brodalumab Dose in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body WeightCompletedNCT04306315Phase 4
• An Alternative Dose Interval Study in Participants With Hidradenitis Suppurativa Receiving BrodalumabWithdrawnNCT04249713Early Phase 1
• A Phase 4 Clinical Study of BrodalumabCompletedNCT04183881Phase 4
• A Study of KHK4827 in Subjects With Palmoplantar PustulosisCompletedNCT04061252Phase 3
• Biomarkers In Hidradenitis Suppurativa Participants Receiving BrodalumabCompletedNCT03960268Early Phase 1
• A Phase 3 Study of KHK4827 in Patients With Systemic SclerosisCompletedNCT03957681Phase 3
• Treatment of Moderate Hidradenitis SuppurativaStatus unknownNCT03910803Phase 2
• Effect of Brodalumab Compared to Placebo on Vascular Inflammation in Moderate-to-severe PsoriasisStatus unknownNCT03478280Phase 4
• An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric SubjectsActive, not recruitingNCT03240809Phase 4
• A Study of Brodalumab in Subjects With Axial Spondyloarthritis (axSpA)CompletedNCT02985983Phase 3
• A Study of KHK4827 (Brodalumab) in Subjects With Moderate to Severe Psoriasis in KoreaCompletedNCT02982005Phase 3
• Study to Evaluate Broadlumab vs Placebo and UstekinumabTerminatedNCT02786732Phase 3
• A Phase 3 Clinical Study of KHK 4827CompletedNCT02052609Phase 3
• An Open-label, Non-controlled Study of KHK4827 in Subjects With PsoriasisCompletedNCT01782937Phase 3
• A Phase 3 Clinical Study of KHK4827CompletedNCT01782924Phase 3
• A Phase 2 Clinical Study of KHK4827CompletedNCT01748539Phase 2
• A Clinical Pharmacology of KHK4827 in Healthy Volunteers and Subject With Moderate to Severe PsoriasisCompletedNCT01488201Phase 1

← Brodalumab overview